Business / Finance

RSS

Rockwell Medical fourth quarter net loss increases to $1.7 million

Rockwell Medical, a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD) and iron deficiency anemia, reported today fourth quarter and full-year 2010 results.

3 Mar 2011

Corporations brace for health law gains and losses

Two corporations offer very different views of how changes resulting from the health overhaul will impact their bottom lines.

3 Mar 2011

International Surf Resorts to acquire BioZone Laboratories

International Surf Resorts, Inc., to be renamed BioZone Pharmaceuticals, Inc., today announced a binding option and letter of intent with BioZone Laboratories, Inc. and related companies.

2 Mar 2011

Cyberonics third quarter net sales increase 15.3% to $47.1 million

Cyberonics, Inc., a global leader in epilepsy management, today announced results for the quarter ended January 28, 2011.

2 Mar 2011

Reliv fourth-quarter net sales decrease to $18.5 million

Reliv International, Inc. a maker of nutritional supplements that promote optimal health, today reported its financial results for the fourth-quarter and full-year of 2010.

2 Mar 2011

Achillion fourth quarter revenue is $2 million for three months ended December 31, 2010

Achillion Pharmaceuticals, Inc., a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today reported financial results for the three and twelve months ended December 31, 2010.

2 Mar 2011

Mylan confirms lawsuit relating to Estradiol Transdermal System ANDA

Mylan Inc. today confirmed that the company has been sued by Vivelle Ventures LLC, Noven Pharmaceuticals Inc. and Novartis Pharmaceuticals Corporation in connection with the filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for Estradiol Transdermal System, USP (Twice-Weekly), 0.025 mg/day, 0.0375 mg/day, 0.05 mg/day, 0.075 mg/day and 0.1 mg/day.

2 Mar 2011

Ipsen 2010 total revenues increase 5.2% to €1,170.3 million

In 2010, Group drug sales grew 5.1% year-on-year - at constant currency - exceeding the objective set a year ago of 3.0% to 5.0%, fuelled notably by the sales of Specialty Care products throughout all the geographical regions where the Group operates.

2 Mar 2011

Thermo Fisher Scientific plans for new manufacturing facility in China

Thermo Fisher Scientific Inc., the world leader in serving science, today announced plans for a new manufacturing facility in China within the Suzhou Science and Technology Town - part of the company's strategy to aggressively expand its presence in the Asia-Pacific region.

From Thermo Fisher Scientific Inc. 2 Mar 2011

GenMark announces dismissal of microfluidic technology patent lawsuit against Caliper Life Sciences

GenMark Diagnostics Inc. announced today that it has dismissed a lawsuit in the Northern District of California pending since November 2010 that requested declaratory relief that it does not infringe three U.S. patents on microfluidic technology allegedly owned by Caliper Life Sciences, Inc.

2 Mar 2011

Advion to establish new laboratory at Purdue Research Park near Indianapolis

Advion BioServices Inc., a provider of contract bioanalytical research services, announced that it will establish a laboratory here, creating 49 immediate jobs and up to 66 jobs by 2015.

From Advion 2 Mar 2011

Market demands shape health sector growth

The Wall Street Journal reports on how a string of recent acquisitions are being spurred by an increased demand for outpatient facilities and senior care. However, The Washington Post reports that some specific facilities — those that are doctor-owned, for instance — are sparking criticism.

1 Mar 2011

Pfizer acquires King Pharmaceuticals

Pfizer Inc. today announced that it has combined operations with King Pharmaceuticals, Inc. On February 28, 2011, Pfizer completed its acquisition of King through the merger of its wholly owned subsidiary, Parker Tennessee Corp., with and into King. King is now a wholly owned subsidiary of Pfizer.

1 Mar 2011

Tengion prices $31.4 million through private placement financing

Tengion, Inc., a leader in regenerative medicine, today announced that it has entered into definitive agreements with certain investors in connection with a PIPE financing transaction pursuant to registration exemptions under the Securities Act of 1933, as amended.

1 Mar 2011

QLT fourth quarter revenues decrease 7.3% to $10.0 million

QLT Inc. today reported financial results for the fourth quarter ended December 31, 2010 and full year 2010 as well as issued its guidance for 2011. Unless specified otherwise, all amounts are in U.S. dollars and in accordance with U.S. GAAP.

1 Mar 2011

Intercell reports EUR 255.2m net loss for full year 2010

Today Intercell AG announced its financial results for Q4 and the preliminary results for the full financial year 2010 and presented an update on the Company's development programs.

1 Mar 2011

Excella achieves SafeBridge Potent Compound Safety Certification

SAFEBRIDGE® CONSULTANTS, INC., headquartered in Mountain View, California, has announced that Excella GmbH in Feucht, Germany has met the criteria established under the SafeBridge program for "Potent Compound Safety Certification" and has been deemed competent and proficient in the safe handling of potent active pharmaceutical ingredients ("APIs") and potent drug products.

1 Mar 2011

LifeWatch fourth quarter revenues increase 11.9% to $21.9 million

LifeWatch AG, the leading provider of wireless telemedicine, today announces the results for the fourth quarter 2010 and full fiscal year 2010 and provides an outlook for 2011. LifeWatch marked the end of a challenging year with a return to growth and profitability in the fourth quarter of 2010.

1 Mar 2011

LEO selects Veeva CRM to support its rapidly growing New Markets Europe region

LEO Pharma, a leading global pharmaceutical company specialising in dermatology and critical care, has selected Veeva CRM to support its rapidly growing New Markets Europe region. LEO has started the deployment of Veeva CRM to its users in countries such as Hungary, Czech Republic, Slovakia, Poland, Romania, and Italy.

1 Mar 2011

On Assignment acquires Valesta

On Assignment, Inc. announced today it has closed its acquisition of Valesta, a privately owned provider of specialized staffing in the area of clinical research within Western Europe. This acquisition close follows the Letter of Intent executed and announced on December 22, 2010, and the SPA announced on February 23, 2011.

1 Mar 2011